Nilaya Varma, Group CEO and Co-founder, Primus Partners, highlights India’s strong potential to lead in manufacturing GLP-1-based therapies like semaglutide and tirzepatide, with the global market expected to exceed $150 billion by 2030. While India's peptide CDMO sector currently makes up just 3% of the $190 billion global market, it is projected to grow at 14% annually. However, Varma cautions that peptide production remains complex and costly, hindered by challenges such as limited availability of protected amino acids, specialized reagents, and the need for advanced purification processes.